NO911303L - Produksjon av biologisk aktive, rekombinante medlemmer avngf/bdnf-familien til neurotrofiske proteiner. - Google Patents

Produksjon av biologisk aktive, rekombinante medlemmer avngf/bdnf-familien til neurotrofiske proteiner.

Info

Publication number
NO911303L
NO911303L NO91911303A NO911303A NO911303L NO 911303 L NO911303 L NO 911303L NO 91911303 A NO91911303 A NO 91911303A NO 911303 A NO911303 A NO 911303A NO 911303 L NO911303 L NO 911303L
Authority
NO
Norway
Prior art keywords
bdnf
avngf
production
neurotrophic proteins
ngf
Prior art date
Application number
NO91911303A
Other languages
English (en)
Other versions
NO308308B1 (no
NO911303D0 (no
Inventor
Frank D Collins
Jack Lile
Susan Bektesh
Drzislav Mismer
Tadahiko Kohno
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO911303(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of NO911303D0 publication Critical patent/NO911303D0/no
Publication of NO911303L publication Critical patent/NO911303L/no
Publication of NO308308B1 publication Critical patent/NO308308B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • C07K14/503Fibroblast growth factor [FGF] basic FGF [bFGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/848Escherichia
    • Y10S435/849Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
NO911303A 1990-04-06 1991-04-03 Produksjon av biologisk aktive, rekombinante medlemmer av NGF/BDNF-familien til neurotrofiske proteiner NO308308B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50544190A 1990-04-06 1990-04-06
US54775090A 1990-07-02 1990-07-02
US07/594,126 US5235043A (en) 1990-04-06 1990-10-09 Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins

Publications (3)

Publication Number Publication Date
NO911303D0 NO911303D0 (no) 1991-04-03
NO911303L true NO911303L (no) 1991-10-07
NO308308B1 NO308308B1 (no) 2000-08-28

Family

ID=27414291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO911303A NO308308B1 (no) 1990-04-06 1991-04-03 Produksjon av biologisk aktive, rekombinante medlemmer av NGF/BDNF-familien til neurotrofiske proteiner

Country Status (17)

Country Link
US (1) US5235043A (no)
EP (1) EP0450386B1 (no)
JP (1) JP2521851B2 (no)
KR (1) KR910018545A (no)
AT (1) ATE183232T1 (no)
AU (1) AU651339B2 (no)
CA (1) CA2038669C (no)
DE (1) DE69131514T2 (no)
DK (1) DK0450386T3 (no)
ES (1) ES2140379T3 (no)
FI (1) FI108146B (no)
GR (1) GR3031632T3 (no)
IE (1) IE910827A1 (no)
IL (1) IL97602A (no)
NO (1) NO308308B1 (no)
NZ (1) NZ237544A (no)
TW (1) TW206258B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
ES2119779T3 (es) * 1990-09-05 1998-10-16 Southern Cross Biotech Pty Ltd Solubilizacion de proteinas en formas activas.
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
NZ243084A (en) * 1991-06-12 1995-08-28 Regeneron Pharma Production and recovery of recombinant neurotrophins, genes for a modified lamb signal sequence, fusion genes and plasmids
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
DK0642580T3 (da) * 1992-05-18 2002-12-23 Genentech Inc Hepactocytvækstfaktorvarianter
EP0573904B1 (en) * 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Therapeutic agent for neutropenia
US5364645A (en) * 1992-10-30 1994-11-15 The Regents Of The University Of California Method of controlling microorganisms by pulsed ultraviolet laser radiation
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
ATE175677T1 (de) * 1993-10-18 1999-01-15 Regeneron Pharma Heterodimere der wachstumsfaktoren
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5607711A (en) * 1995-11-01 1997-03-04 The Regents Of The University Of California Method of controlling insects and mites with pulsed ultraviolet light
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US7015316B1 (en) 1996-03-14 2006-03-21 Washington University Polynucleotides encoding human persephin and related growth factors
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
NZ329482A (en) 1996-03-14 2000-05-26 Univ Washington A growth factor persephin related to the GDNF/neurturin family of growth factors Methods of treating conditions related to persephin deficiency detecting gene alterations and identifying other members of the family are included
EP0904355B1 (de) * 1996-06-11 2004-03-03 Boehringer Mannheim Gmbh Verfahren zur aktivierung von denaturiertem protein
US5910435A (en) * 1996-07-25 1999-06-08 Wisconsin Alumni Research Foundation Method of folding proteins with synthetic dithiol catalysts
HU222666B1 (hu) 1996-11-15 2003-09-29 Genentech, Inc. Eljárás neuorotrofinok tisztítására
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
EP0994188B1 (de) * 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6329136B1 (en) 1998-10-30 2001-12-11 The Regents Of The University Of California Method for laser inactivation of infectious agents
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US20020049303A1 (en) * 1999-06-28 2002-04-25 Tang Jordan J. N. Catalytically active recombinant memapsin and methods of use thereof
US6545127B1 (en) * 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
EP1206578A2 (en) 1999-08-11 2002-05-22 Whitehead Institute For Biomedical Research Bdnf polymorphism and association with bipolar disorder
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US20030232365A1 (en) * 2001-02-15 2003-12-18 Whitehead Institute For Biomedical Research BDNF polymorphisms and association with bipolar disorder
EP1233075A3 (en) * 2001-02-15 2003-01-08 Whitehead Institute For Biomedical Research BDNF polymorphism and association with bipolar disorder
AU2002359301B2 (en) * 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
WO2008002572A2 (en) * 2006-06-27 2008-01-03 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for measuring mature brain derived neurotrophic factor
IT1394596B1 (it) * 2008-09-30 2012-07-05 Fond Parco Tecnologico Padano Produzione di ngf in pianta.
EP2594295A1 (en) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nerve implants based on a compacted biomaterial containing cells
GB201804641D0 (en) * 2018-03-22 2018-05-09 Inivata Ltd Methods of sequencing nucleic acids and error correction of sequence reads
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita
EP4413993A1 (en) * 2023-02-10 2024-08-14 Dompe' Farmaceutici S.P.A. Method of obtaining recombinant human brain-derived neurotrophic factor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US6709837B1 (en) * 1989-03-10 2004-03-23 Takeda Chemical Industries, Inc. Polypeptide and production thereof
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
JPH05161493A (ja) * 1989-08-30 1993-06-29 Max Planck Ges Foerderung Wissenschaft Ev ニューロトロフィン―3

Also Published As

Publication number Publication date
CA2038669C (en) 2004-06-29
ES2140379T3 (es) 2000-03-01
JPH06319549A (ja) 1994-11-22
ATE183232T1 (de) 1999-08-15
CA2038669A1 (en) 1991-10-07
IE910827A1 (en) 1991-10-09
DE69131514T2 (de) 2000-05-04
IL97602A (en) 2005-08-31
AU651339B2 (en) 1994-07-21
KR910018545A (ko) 1991-11-30
NZ237544A (en) 1993-07-27
FI108146B (fi) 2001-11-30
EP0450386A3 (en) 1992-09-09
JP2521851B2 (ja) 1996-08-07
DE69131514D1 (de) 1999-09-16
FI911643A0 (fi) 1991-04-05
NO308308B1 (no) 2000-08-28
EP0450386B1 (en) 1999-08-11
DK0450386T3 (da) 2000-03-06
NO911303D0 (no) 1991-04-03
GR3031632T3 (en) 2000-01-31
FI911643A (fi) 1991-10-07
TW206258B (no) 1993-05-21
IL97602A0 (en) 1992-06-21
AU7413091A (en) 1991-11-14
US5235043A (en) 1993-08-10
EP0450386A2 (en) 1991-10-09

Similar Documents

Publication Publication Date Title
NO911303L (no) Produksjon av biologisk aktive, rekombinante medlemmer avngf/bdnf-familien til neurotrofiske proteiner.
ATE383424T1 (de) Polypeptide, deren herstellung und verwendung
HU9303182D0 (en) Truncated forms of the hepatocite growth factor (hgf) receptor pharmaceutical compositions containing them and process for production off them
EP0769554A3 (en) Human CNP gene and precursor protein
HUT52544A (en) Process for production of artery-system anticoagulant proteins and dns coding them
DE69533443D1 (de) Die herstellung von biologisch aktiven, rekombinanten und neurotrophem protein
DE69203254D1 (de) Herstellung von Crackkatalysatoren und Crackverfahren mit diesen.
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
DK0443874T3 (da) Vektorer og forbindelser til ekspression af glycosyleringsmutanter af humanprotein C
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
AR243237A1 (es) Un vector de expresion recombinante que contiene una secuencia de adn que codifica el factor neurotrofico ciliar humano,un microorganismo e.coli transformado,y linea celulares transformadas.
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
ZA911834B (en) Production of biologically active,recombinant members of the ngf/bdnf family of neurotrophic proteins
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ATE111955T1 (de) Herstellung von rekombinantem, menschlichem psti.
DE69434782D1 (de) Verfahren zur herstellung rekombinanter, biologisch aktiver polypeptide
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
ATE209500T1 (de) Ein neuartiges, antineoplastisches cytokin
EP0497911A4 (en) Recombinant production of lactoperoxidase
DE59509921D1 (de) Integrationsvektoren zur Herstellung von Genen, die rekombinante Antikörper codieren
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
IT1254703B (it) Processo per la sintesi e la purificazione di forme troncate del fattore neuronotrofico ciliare umano
DE69123242D1 (de) Physiologisch aktive Peptide, ihre Verwendung und eine Methode besagte Peptide herzustellen
MX9606388A (es) Formas truncadas de la proteina inhibidora kappa b (i kappa b alfa), produccion recombinante de dicha proteina y sus usos.

Legal Events

Date Code Title Description
MK1K Patent expired